AZACS
AZACS
Azithromycin in Acute Coronary Syndrome. A trial which asked whether the evidence suggesting an association between Chlamydia pneumoniae infection and coronary artery disease was real, and, if so, would short-term treatment with the macrolide antibiotic azithromycin reduce recurrent ischaemic events in patients admitted for unstable angina or acute myocardial infarction.Endpoint
Death, recurrent MI, recurrent ischaemia necessitating revascularisation.
Logistics
Randomised, double-blind, placebo-controlled, multicentre; 1439 patients to receive azthromycin or placebo.
Conclusion
No association between Chlamydia pneumoniae infection and coronary artery disease (and thus, no benefit of azithromycin treatment).